# Re-evaluation Task: HN3-033

## Context
- **Case ID**: HN3-033
- **Cancer type**: Laryngeal Chondrosarcoma of Cricoid Cartilage
- **Stage**: Grade I (low-grade), IDH1 R132H mutated
- **Molecular profile**: IDH1 R132H mutation, Low-grade (Grade I), D-2-hydroxyglutarate (2-HG) overproduction
- **Report file**: experiment_reports\HN3-033_report.json
- **Current score**: 66/100
- **Gap analysis (local GPU)**: The lack of data on Ivosidenib and Olutasidenib, two mutant IDH1 inhibitors, hinders the understanding of their efficacy in treating cancer patients with specific genetic mutations, which is a critical gap that needs to be addressed to improve the score. Additionally, the absence of sample sizes for Dasatinib, a SRC kinase inhibitor for IDH-mutant chondrosarcoma, limits the ability to assess its safety and effectiveness in this patient population.

## Current dimension scores
| Dimension | Score | % of max |
|---|---|---|
| rating_calibration                  |   0/15  |   0.0% |
| evidence_depth                      |  11/25  |  44.0% |
| clinical_relevance                  |   8/10  |  80.0% |
| combo_supportive_coverage           |   8/10  |  80.0% |
| source_quality                      |  14/15  |  93.3% |
| structural_integrity                |  15/15  | 100.0% |
| tier_coverage                       |  10/10  | 100.0% |

## Target dimension: `rating_calibration` (0.0% of max)

## Your instructions

Read the full report JSON at `experiment_reports\HN3-033_report.json`.

Your task: Fix ONLY the `rating_breakdown` fields in the `treatments` array.

For each treatment, verify:
1. `evidence_level.score` matches the actual study phase:
   - Phase 3 RCT (N>=500, top journal) = 9-10
   - Phase 3 RCT (N<500) = 7-8
   - Phase 2 = 5-7
   - Phase 1 = 2-4
   - Case series / retrospective = 1-3
2. `survival_benefit.score` matches actual OS delta:
   - >12 months delta = 9-10
   - 6-12 months = 7-8
   - 3-6 months = 5-6
   - 1-3 months = 3-4
   - <1 month or no control = 1-2
3. `composite_rating` = weighted average (evidence 30%, survival 30%, access 15%, safety 15%, biomarker 10%)
4. Treatments must be re-sorted descending by composite_rating after changes

Do NOT change any other field. Return the complete corrected `treatments` array only.

## Output format

Return a valid JSON object containing ONLY the corrected section (e.g., `{"treatments": [...]}` or `{"sources": [...]}`).

Do NOT return the full report — only the corrected array. The runner will merge it back.

After returning the JSON, add one line:
`SCORE_IMPACT: <estimated new score>/100`

## Report JSON (for reference)

```json
{
  "report_metadata": {
    "generated_date": "2026-03-23",
    "cancer_type": "Laryngeal Chondrosarcoma of Cricoid Cartilage",
    "stage": "Grade I (low-grade), IDH1 R132H mutated",
    "molecular_profile": [
      "IDH1 R132H mutation",
      "Low-grade (Grade I)",
      "D-2-hydroxyglutarate (2-HG) overproduction"
    ]
  },
  "treatments": [
    {
      "rank": 1,
      "name": "Transoral Endoscopic Resection (Conservative Cricoidectomy)",
      "category": "Standard of Care",
      "composite_rating": 0,
      "rating_breakdown": {
        "evidence_level": {
          "score": 8,
          "rationale": "Multiple case series with long-term follow-up showing 100% 5-year OS and 85.7% 5-year DFS for endoscopic resection of low-grade cricoid chondrosarcoma; scoping review supports conservative approach"
        },
        "survival_benefit": {
          "score": 9,
          "rationale": "5-year OS 100% and DFS 85.7% with mean follow-up of 80 months; grade I laryngeal chondrosarcoma has 253.8 month median survival; recurrences treatable with repeat resection"
        },
        "accessibility": {
          "score": 8,
          "rationale": "Available at centers with transoral surgical expertise; requires specialized endoscopic equipment and experienced head/neck surgeon"
        },
        "safety_profile": {
          "score": 8,
          "rationale": "No tracheostomy required; no subglottic stenosis; preserves voice and swallowing; minimal morbidity compared to total laryngectomy"
        },
        "biomarker_match": {
          "score": 10,
          "rationale": "Standard treatment for all low-grade cricoid chondrosarcomas regardless of IDH mutation status"
        }
      },
      "mechanism_of_action": "Transoral endoscopic surgical removal of the chondrosarcoma from the cricoid cartilage using CO2 laser or cold instruments, preserving the laryngeal framework. Partial cricoidectomy removes the tumor-bearing cartilage while maintaining airway patency, voice production, and swallowing function.",
      "key_evidence": {
        "study_name": "Transoral Endoscopic Resection of Low-Grade, Cricoid Chondrosarcoma",
        "journal": "Annals of Surgical Oncology",
        "year": 2014,
        "sample_size": 7,
        "os_months": {
          "treatment": 80,
          "control": 0,
          "hazard_ratio": 0,
          "p_value": 0
        },
        "pfs_months": {
          "treatment": 80,
          "control": 0
        },
        "orr_percent": {
          "treatment": 100,
          "control": 0
        }
      },
      "biomarker_requirements": [],
      "notable_side_effects": [
        "Temporary dysphonia",
        "Mild dysphagia (temporary)",
        "Local recurrence (14.3%, treatable with re-resection)",
        "Rare subglottic stenosis"
      ],
      "availability": "Available at specialized head and neck centers",
      "source_urls": [
        "https://link.springer.com/article/10.1245/s10434-014-3668-8",
        "https
... (truncated — read full file from experiment_reports\HN3-033_report.json)
```
